Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Computer tool opens up new ways to address antibiotic resistance - 02/07/2025 Graphic and symbolic explanation of how PhARIS works. Phages are analysed and thus identified.

    PhARIS identifies effective phages against multi-resistant bacteria

    Bacteriophages - viruses that specifically attack and destroy bacteria - are emerging as promising alternatives to antibiotics in the fight against drug-resistant infections. To speed this effort, researchers have created PhARIS, a computational tool that mines genomic data to pinpoint phages that are effective against S. aureus. By rapidly matching phage and pathogen, PhARIS can accelerate the development of targeted phage therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharis-identifies-effective-phages-against-multi-resistant-bacteria
  • Press release - 11/06/2025

    Antiviral tests on protective clothing for infection control

    Textiles functionalized with antiviral agents are intended to reduce the risk of transmission of pathogens, particularly in a medical environment. These antiviral properties must be carefully tested and verified in laboratory tests. The biological testing laboratory of the German Institutes of Textile and Fiber Research Denkendorf has examined antiviral activities with coronaviruses as part of a research project on textiles for infection control.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antiviral-tests-protective-clothing-infection-control
  • Press release - 22/05/2025

    Six Clusters of Excellence for the University of Tübingen

    Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
  • Press release - 19/05/2025

    How the Epstein-Barr virus promotes its spread in the body

    Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
  • New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025 Hydroborierung_synthetische-Immunologie.png

    Bottom-up synthetic immunology for novel therapeutic approaches

    Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bottom-synthetic-immunology-novel-therapeutic-approaches
  • Press release - 02/04/2025

    New antibiotic for multidrug resistant superbug

    Researchers from the universities in Konstanz and Vienna discover a new class of antibiotic that selectively targets Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. These substances trigger a self-destruction program, which also operates in multi-resistant variants of the pathogen. The novel findings are published in the current issue of Nature Microbiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-antibiotic-multidrug-resistant-superbug
  • Press release - 19/03/2025

    Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori

    Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
  • Press release - 14/03/2025

    Tool identifies specific viruses to combat dangerous bacteria

    University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tool-identifies-specific-viruses-combat-dangerous-bacteria
  • Press release - 27/02/2025

    EU Project: New Molecular Interventions against Virus Infections

    Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-project-new-molecular-interventions-against-virus-infections
  • Press release - 10/02/2025

    Medical textiles with infection protection

    In collaboration with Heraeus, the German Institutes of Textile and Fiber Research (DITF) are developing fibers and textiles with a novel infection protection system. The basis is an antimicrobial mechanism of action licensed from Heraeus and marketed under the name AGXX. The goal of the collaboration is to optimally integrate the AGXX technology into textile finishes and coatings and to incorporate it into fiber-spinnable polymers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/medical-textiles-infection-protection
  • Press release - 16/01/2025

    New weapons against viruses

    Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-weapons-against-viruses
  • Press release - 28/11/2024

    Molecular biology: New interdisciplinary Research Training Group investigates cellular regulation

    Cell division, cell differentiation, cell repair and cell death play fundamental roles in the human organism, its development, health and reproduction. Cellular transformation processes are governed by two regulatory mechanisms: chromatin modifications and cell signaling networks. The EpiSignal Research Training Group sheds light on the hitherto little-researched interplay between these two complex systems.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biology-new-interdisciplinary-research-training-group-investigates-cellular-regulation
  • Press release - 05/11/2024

    Heidelberg scientist receives highly endowed EC synergy grant

    Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-scientist-receives-highly-endowed-ec-synergy-grant
  • Press release - 12/06/2024

    Pathogen identification — next-generation sequencing optimizes diagnostics

    Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pathogen-identification-next-generation-sequencing-optimizes-diagnostics
  • App for tuberculosis diagnosis - 15/05/2024 The photo shows a collection of pink-coloured, elongated bacteria against a dark background

    "Find-TB" aims to improve access to tuberculosis diagnostics

    Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/find-tb-aims-improve-access-tuberculosis-diagnostics
  • Press release - 13/05/2024

    Detecting respiratory infections: simply blow for diagnosis

    Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis
  • Press release - 24/04/2024

    CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

    Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
  • Press release - 19/04/2024

    Electrified bacteria

    PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom
  • Press release - 18/04/2024

    Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform

    The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
  • Press release - 10/04/2024

    Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform

    With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
  • Press release - 15/01/2024

    Maturation instead of cell death: Defective signalling pathways disrupt immune cell development

    Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.

    https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development
  • Press release - 18/12/2023

    Researchers discover novel antibiotic substance from the human nose

    For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
  • Computer-assisted genome mining - 04/12/2023 Five photographs of soil, plants, sea, herbs and mouldy fruit show the different habitats of bacteria and fungi. Arrows lead to different chemical compounds.

    Natural product genomics opens up new avenues in the search for antibiotics

    Antibiotic-resistant pathogens are increasingly endangering our health. Since most of the drugs currently in use are based on secondary metabolites produced by bacteria or fungi, the research group of Prof. Dr. Nadine Ziemert in Tübingen is developing bioinformatic tools to specifically search the genome of these organisms for previously unknown antimicrobial agents.

    https://www.gesundheitsindustrie-bw.de/en/article/news/natural-product-genomics-opens-new-avenues-search-antibiotics
  • Press release - 30/11/2023

    Taking antibiotics back in time

    University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time
  • Press release - 29/11/2023

    EU funds research into causes and new therapies for multiple sclerosis

    The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-foerdert-forschung-zu-ursachen-und-neuen-therapien-der-multiplen-sklerose
  • Nanoparticles as drug carriers - 09/11/2023 Zu sehen ist eine Mikroskopie-Aufnahme, die mit Mykobakterien infiziertes Lungengewebe inklusive Nanocarrier zeigt.

    Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens

    Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-nanocarriers-antibiotics-against-resistant-tuberculosis-pathogens
  • Press release - 26/10/2023

    Innovative research aims to improve wound healing and cancer therapy

    Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-forschung-soll-wundheilung-und-krebstherapie-verbessern
  • Press release - 20/10/2023

    Why tuberculosis bacteria form long chains

    A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-tuberculosis-bacteria-form-long-chains
  • Press release - 18/10/2023

    SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease

    Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
  • Press release - 20/06/2023

    Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future

    KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
  • Press release - 22/05/2023

    Prevention of pandemics

    Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-pandemics
  • Press release - 16/05/2023

    Mast cells have an important impact on the development of chronic myeloid leukemia

    Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
  • Press release - 01/03/2023

    Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells

    Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
  • Press release - 17/01/2023

    Sugar-based inhibitors disarm the pathogen Pseudomonas aeruginosa

    The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zuckerbasierte-inhibitoren-entwaffnen-den-krankheitserreger-pseudomonas-aeruginosa
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Press release - 09/12/2022

    Epigenetic emergency switch improves defense against infections

    During infections, the hematopoietic system switches from normal to emergency mode. This improves the defense against the pathogens. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found an epigenetic switch in blood stem cells and progenitor cells of mice that can trigger the switch from one mode to the other.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-emergency-switch-improves-defense-against-infections
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Press release - 20/10/2022

    Cytoskeleton acts as cells’ bouncer for bacteria

    Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 01/09/2022

    Personalised antibiotic treatment strategies for tuberculosis patients

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
  • Press release - 04/08/2022

    Inflammation accelerates aging of the hematopoietic system

    In mice, inflammation in early to mid-life leads to a permanent decline in functional blood stem cells, according to a recent publication by scientists from the German Cancer Research Center (DKFZ) and the Stem Cell Institute HI-STEM*. The ability of the blood stem cells to regenerate was suppressed for at least one year after challenge with inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/inflammation-accelerates-aging-hematopoietic-system
  • Assay to support the diagnosis of autoimmune diseases - 22/06/2022 Immunkomplexe_sIC-assay_Teaser.jpg

    Tracking down pathogenic immune complexes

    Soluble complexes of antibodies and their target structures circulating in the blood can trigger serious systemic inflammations. Dr. Philipp Kolb and Haizhang Chen from the Institute of Virology at the Freiburg University Medical Centre have developed a sensitive, cell-based test system for detecting these immune complexes. The system can be used to diagnose systemic autoimmune diseases, and also severe cases of COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tracking-down-pathogenic-immune-complexes
  • Press release - 20/06/2022

    Protein changes in the liquor indicate inflammatory processes in the brain

    Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain
  • Press release - 12/05/2022

    New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses

    While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Press release - 12/04/2022

    Technology transfer award for PCR rapid test device for infection diagnostics

    Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
  • Macrophages interacting with cytomegaloviruses - 22/02/2022 Graphik_CMV_Makrophagen_Teaser.jpg

    Cytomegaloviruses subvert macrophage identity

    Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
  • Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Nahaufnahme eines Multiplex-Chips mit roten oder blauen Kanälen, der zwischen zwei Fingern in blauen Handschuhen gehalten wird.

    Antibiotic detection from whole blood or exhaled breath possible

    Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
  • Viral zoonoses - 24/01/2022 Schematic drawing of a flavivirus polyprotein anchored in the ER membrane. The different viral proteins are indicated by differently coloured sections on the polyprotein that is marked with dashes and the protease interfaces are marked by arrows.

    Development of inhibitors that help stop viral zoonoses

    Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
  • Press release - 19/11/2021

    Keep an eye on us! – Bacteria on slit lamps

    Furtwangen University publishes the world’s first molecular biological study on bacterial contamination of slit lamps. Slit lamps are among the most important tools used by ophthalmologists and opticians. They allow selected areas of the eye to be magnified and examined for diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/keep-eye-us-bacteria-slit-lamps
  • Booster for neutrophil granulocytes - 27/10/2021 acetat-aktivierung_Bearbeitet.jpg

    Acetate supports immune cells to fight against sepsis

    Blood poisoning is the most dangerous complication of bacterial infections and often leads to death. Researchers at the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen have now identified acetate as a potent agent for stimulating innate immune system cells, supporting their ability to destroy bacteria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/acetate-supports-immune-cells-fight-against-sepsis
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
  • Press release - 13/07/2021

    Breakthrough in research on age-related macular degenerationtion

    Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
  • Press release - 25/05/2021

    From harmless skin bacteria to dreaded pathogens

    The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/harmless-skin-bacteria-dreaded-pathogens
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines - a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Signal mechanisms in inflammatory processes - 18/05/2021 aktivierte-makrophagen.jpg

    Newly discovered substances activate the inflammasome in macrophages

    Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-substances-activate-inflammasome-macrophages
  • Article - 29/04/2021 aufbau-antikoerper.jpg

    Nanobodies for determining neutralising antibodies after corona infection

    After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanobodies-determining-neutralising-antibodies-after-corona-infection
  • Article - 17/03/2021 Schematische Abbildung des Tetracyclin-induzierbaren epigenetischen Gedächtnissystems in einem Escherichia coli Bakterium.

    Epigenetic switches in bacteria as biosensors

    The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…

    https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetic-switches-bacteria-biosensors
  • Press release - 15/03/2021

    How novel pathogens may cause the development of colorectal cancer

    Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-novel-pathogens-may-cause-development-colorectal-cancer
  • Press release - 24/02/2021

    Supposedly "silent" mutation with serious consequences

    So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
  • Article - 17/02/2021 Messerer_Bild_2.jpg

    Whole blood model enables development of early warning system for sepsis

    Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

    https://www.gesundheitsindustrie-bw.de/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
  • Press release - 01/02/2021

    Targeting a rapid market breakthrough for new vaccine production method

    In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-rapid-market-breakthrough-new-vaccine-production-method
  • Press release - 18/01/2021

    How a protein variant could explain resistance to sleeping sickness drug

    A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
  • Infection control - 07/01/2021 Elektronenmikroskopische Aufnahme von pink gefärbten Staphylococcus aureus Bakterien auf einer lila gefärbten Zelloberfläche.

    Gene accordions as potential markers for pathogenic properties

    Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • CeGat GmbH - 06/08/2020 Cegat_Teaser.jpg

    CeGaT: Specific coronavirus antibody test for all

    Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
  • Prime Vector Technologies GmbH - 09/04/2020

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Article - 26/07/2019 Jeney_Bild1.jpg

    New test assay leads to discovery of new influenza virus infection route

    Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/alternativer-infektionsweg-fuer-grippeviren-durch-neues-testverfahren-entdeckt
  • Article - 11/06/2019 A portrait by Harald Zur Hausen

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Expert interview on NTDs – part 2 - 29/05/2019 The photo shows good footwear and people sitting in front of the shoes. Only the legs and feet can be seen. They are oedematous. The ground on which the shoes are standing is of a sandy texture and partially covered with straw.

    Neglected tropical diseases - Gisela Schneider: the burden of disease

    "Leaving no one behind". The motto of the 2030 Agenda with its 17 Sustainable Development Goals (SDGs) which was signed by the United Nations (UN) in 2015 makes clear that combatting poverty and its consequences is an essential part of sustainable development. The fight against neglected tropical diseases (NTDs) is defined as a major aim of the Agenda’s sustainable development goals. The World Health Organisation (WHO) regards twenty…

    https://www.gesundheitsindustrie-bw.de/en/article/news/neglected-tropical-diseases-gisela-schneider-the-burden-of-disease
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search